Ashton-Rickardt Philip 4
4 · Sigilon Therapeutics, Inc. · Filed Feb 22, 2022
Insider Transaction Report
Form 4
Ashton-Rickardt Philip
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-18$1.48/sh+90,000$133,200→ 90,000 totalExercise: $1.48Exp: 2032-02-17→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.